Athena Athena

X

Digital content for Visen Pharmaceuticals

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Visen Pharmaceuticals
China Flag
Country
Country
China
Address
Address
Shanghai
Telephone
Telephone
+86 021 5299 9605
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

https://www.prnewswire.com/news-releases/visen-announces-acceptance-of-a-biologics-license-application-for-lonapegsomatropin-in-china-302082740.html

PR NEWSWIRE
07 Mar 2024

https://www.prnewswire.com/news-releases/double-blind-period-completes-primary-endpoint-analysis-of-phase-3-clinical-trial-to-be-conducted-for-chinas-first-hormone-replacement-treatment-targeting-hypoparathyroidism-301715285.html

PR NEWSWIRE
06 Jan 2023

https://www.prnewswire.com/news-releases/visen-discloses-52-week-clinical-results-for-its-china-phase-3-trial-of-lonapegsomatropin-301681121.html

PRNEWSWIRE
17 Nov 2022

https://www.globenewswire.com/news-release/2022/05/23/2448375/0/en/Positive-Results-from-VISEN-s-Phase-3-Trial-of-Once-Weekly-TransCon-hGH-in-China-Consistent-with-Ascendis-Pharma-s-Phase-3-Height-Trial.html

GLOBENEWSWIRE
23 May 2022

https://www.prnewswire.com/news-releases/visen-pharmaceuticals-announces-top-line-results-of-phase-3-trial-of-once-weekly-lonapegsomatropin-demonstrating-superior-efficacy-comparable-safety-and-tolerability-to-daily-growth-hormone-301552704.html

PRNEWSWIRE
23 May 2022

https://www.prnewswire.com/news-releases/the-first-hormone-replacement-therapy-for-hypoparathyroidism-in-china-obtains-ind-approval-for-phase-iii-clinical-trial-301305526.html

PRNEWSWIRE
03 Jun 2021
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY